Expert Review of Clinical Immunology临床免疫学专家评论
Expert Review of Clinical Immunology(英文缩写 EXPERT REV CLIN IMMU),ISSN 1744-666X,eISSN 1744-8409,中文译名:临床免疫学专家评论 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.124 | Q2 |
| 2022 | 4.400 | Q2 |
| 2023 | 3.900 | Q2 |
| 2024 | 3.700 | Q2 |
| 2025 | 4.000 | Q2 |
Expert Review of Clinical Immunology 最新收录文献
-
1. Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.
PMID:日期:2026-09-24Switching from reference biologics to biosimilars usually occurs for non-medical reasons, such as cost-driven formulary changes. However, despite biosimilars having the same efficacy and similar safety profiles as their reference products, some patients discontinue treatment and 'switchback' to the reference product. In this narrative review, the authors examine the frequency and causes of switchback reported in journal articles and congress abstracts published between 2016 and 2023, evaluating patients who switched from biosimilars back to the reference biologic. As almost all publications focused on tumor necrosis factor inhibitors, and so the authors restricted their analysis to this drug class. Evidence suggests that switchback rates are low, with most studies of at least 100 patients reporting rates of less than 20%. The main reasons for switchback are typically patient-reported loss of effectiveness (usually judged subjectively) and side effects. These findings support the view that the nocebo ('negative placebo') effect is a plausible and likely contributor to switchback. Healthcare professional and patient education on the effectiveness and safety of biosimilars is needed and will be vital to counter misinformation and minimize the nocebo effect, allowing biosimilars to continue contributing to sustainability in healthcare.
-
3. SARS-CoV-2 management strategies in B-Cell-depleted people with multiple sclerosis: from prevention to antiviral treatment.
3. B细胞耗竭的多发性硬化症患者中SARS-CoV-2管理策略：从预防到抗病毒治疗PMID:日期:2026-09-15Multiple sclerosis (MS) is a leading cause of neurological disability in young adults, necessitating early high-efficacy disease-modifying therapies (DMTs). Monoclonal antibodies targeting the CD20 antigen are a cornerstone of effective disease control, but depletion of peripheral B-cells blunts the humoral immune response. This review synthesizes current evidence on COVID-19 risk, prevention and treatment in anti-CD20-treated people with multiple sclerosis (pwMS). A PubMed literature search through June 2026 identified relevant studies on anti-CD20 therapies and COVID-19 in pwMS. While MS itself does not increase COVID-19 susceptibility, anti-CD20-induced immunosuppression predisposes patients to severe COVID-19 outcomes and protracted or relapsing infections. Furthermore, B-cell depletion severely impairs vaccine efficacy, leaving patients with markedly diminished or absent neutralizing antibody responses. To mitigate COVID-19 risks, future strategies should focus on three pillars. First, strategic switching among anti-CD20 antibodies to improve vaccine efficacy. Second, variant-targeted monoclonal antibodies for pre- and post-exposure prophylaxis in patients lacking robust humoral responses. Finally, early administration of direct-acting small-molecule antivirals to halt viral replication before hyperinflammation. Moving forward, integrating real-world data, identifying immunogenetic risk biomarkers, and evaluating long-term combinations of vaccine-passive immunizations will help safely sustain high-efficacy MS treatments.
-
4. Exploring novel and evolved tools in atopic dermatitis diagnosis.
PMID:日期:2026-09-15Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and is clinically and biologically heterogeneous. Its diagnosis remains clinical, supported by validated criteria, with no single confirmatory test, yet the expansion of targeted systemic therapies has intensified the need for objective tools to support diagnosis and stratify patients. This review summarizes the established clinical framework of AD diagnosis and the emerging tools intended to complement it: circulating and skin-derived biomarkers, minimally invasive tape stripping, the skin microbiome, instrumental barrier assessment, noninvasive biofluids, advanced optical imaging (reflectance confocal microscopy, optical coherence tomography and line-field confocal OCT) and artificial-intelligence and digital tools, with attention to special populations. The discussion is informed by a multi-database search (PubMed, Embase, Cochrane Library and Web of Science) to 2026. Clinical diagnosis remains the reference standard, and the experienced clinician still outperforms any single test. The tools reviewed are promising adjuncts for differential diagnosis, endotyping, response prediction and monitoring, but few are standardized or prospectively validated; priorities for validation and equitable clinical integration are outlined.
-
5. Atacicept in IgA nephropathy.
5. Atacicept在IgA肾病中的应用PMID:日期:2026-09-11Immunoglobulin A (IgA) nephropathy is a common kidney disease. The cytokines B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) have key roles in the pathophysiology of IgA nephropathy. Atacicept is an antibody to BAFF and APRIL. An interim analysis of atacicept in a phase 3 trial in IgA nephropathy, has shown it reduces proteinuria with a good safety profile. This is a very promising finding, and long-term results with atacicept, and a similarly promising BAFF and APRIL inhibitors, telitacicept and povetacicept in nephropathy are eagerly awaited. Of particular interest is whether long-term suppression of immunoglobulins with these inhibitors has adverse effects. Further trials will be needed to determine the respective roles of these inhibitors with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARBs) and/or sodium-glucose cotransporter 2 (SGLT 2) inhibitors in IgA nephropathy.
-
6. Follicular lymphoma and the microenvironment: potential targets and biomarkers.
PMID:日期:2026-09-10Follicular lymphoma (FL) is an indolent B cell malignancy characterized by recurrent genetic alterations, yet its clinical course is highly variable and not fully explained by tumor-intrinsic features alone. Increasing evidence highlights the tumor microenvironment (TME) as a critical regulator of disease progression, therapeutic response, and immune escape. FL TME is composed of diverse cellular elements, including T cell subsets, tumor-associated macrophages, stromal cells, and follicular dendritic cells, which collectively provide survival signals and shape immune dysfunction. These interactions have led to the identification of potential therapeutic targets, such as immune checkpoint molecules, macrophage polarization pathways, and stromal-tumor signaling axes. In parallel, microenvironment-derived biomarkers, including specific immune cell compositions, spatial organization patterns, and gene expression signatures, are emerging as important predictors of prognosis and treatment outcomes. Advances in single-cell and spatial profiling technologies have further refined our understanding of TME heterogeneity, enabling the discovery of clinically relevant targets and biomarkers. Together, these insights support a more integrated model of FL biology and provide a foundation for developing microenvironment-directed therapies and precision medicine approaches.
-
7. Emerging treatment strategies in systemic lupus erythematosus: integrating molecular stratification, targeted therapy, and treatment response evaluation.
7. 系统性红斑狼疮的新兴治疗策略：整合分子分层、靶向治疗和治疗反应评估PMID:日期:2026-08-01Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by marked clinical and immunological heterogeneity. Recent advances indicate that SLE comprises multiple molecular endotypes driven by distinct immune pathways, underscoring the need for a precision medicine approach. Literature was identified through searches of PubMed/MEDLINE using keywords including 'systemic lupus erythematosus,' 'precision medicine,' 'biomarkers,' 'multi-omics,' 'lupus nephritis,' 'CAR-T,' and related terms. Landmark clinical trials, translational studies, and recent high-impact publications published through May 2026 were preferentially included. This review summarizes advances in SLE stratification based on immune phenotyping and multi-omics approaches and outlines emerging therapies, including biologics, intracellular inhibitors, and cell-based treatments. It also discusses challenges in clinical trial design and treatment response assessment. Improving outcomes in SLE will require the integration of molecular stratification, mechanism-based therapy, and refined response assessment. However, the routine implementation of precision medicine remains limited by the lack of standardized biomarkers, accessible multi-omics platforms, and validated patient stratification algorithms. The development of standardized, clinically applicable stratification tools together with novel outcome measures will be essential for translating precision medicine into routine clinical practice.
-
8. Direct immunofluorescence in the clinic for pemphigus and pemphigoid diseases.
PMID:日期:2026-08-01Direct immunofluorescence (DIF) is a cornerstone diagnostic tool for autoimmune bullous diseases (AIBDs), providing critical tissue-based visualization of immune deposits. Literatures were searched using Pubmed with DIF and pemphigus or pemphigoid or AIBD as keywords before 20 December 2025. This review details the role of DIF in the diagnoses of AIBDs, both pemphigus and pemphigoid diseases, highlighting characteristic staining patterns. Pemphigus diseases show IgG/IgA/C3 depositions to keratinocyte cell surfaces, while pemphigoid diseases exhibit linear/granular basement membrane zone depositions of various immunoglobulins and complement components. DIF results are usually consistent with H&E pathological results, intraepidermal blisters for pemphigus diseases and subepidermal blisters for pemphigoid diseases. DIF findings are distinct in some subtypes of AIBDs, guiding differential diagnosis and complementing serological assays, such as indirect immunofluorescence, enzyme-linked immunosorbent assays and immunoblotting. DIF remains the diagnostic gold standard for AIBDs, providing indispensable tissue-specific insights, that cannot be fully replaced by serological tests. However, serological tests are more important in monitoring disease activity. Thus, when biopsy is impractical, optimal diagnosis requires synergistic use of both DIF and serological tests.
-
9. Coexisting inflammatory bowel disease and eosinophilic esophagitis: moving beyond parallel narratives to an integrated framework.
PMID:日期:2026-08-01Eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) are chronic immune-mediated gastrointestinal disorders traditionally framed as biologically distinct, yet epidemiologic data increasingly support a bidirectional association. This narrative review examines the epidemiology,immunopathogenesis, and clinical implications of coexisting EoE and IBD using a targeted PubMed search through 2025 with reference-list screening. Although EoE is classically driven by type 2 inflammation and IBD by Th1/Th17 pathways, both disorders converge on epithelial barrier injury, innate immune dysregulation, and fibroblast-mediated remodeling. These shared downstream mechanisms may help explain diagnostic overshadowing, treatment resistance, and an increased propensity for fibrostenotic complications in patients with dual disease. Coexisting EoE and IBD may be better viewed less as a chance overlap and more as a potentially meaningful clinical association. A mechanism-based approach that incorporates risk enrichment, early endoscopic evaluation, nutritional comanagement, and therapies directed at shared inflammatory-fibrotic pathways may improve outcomes. Future progress will depend on prospective cohorts, biomarker development, and trials that intentionally include patients with both conditions.
-
10. Complicated and refractory celiac disease: a model of antigen-independent immune escape and lymphoproliferation.
PMID:日期:2026-08-01Celiac disease (CeD) is an immune-mediated enteropathy triggered by dietary gluten and treated with a gluten-free diet. However, a subset of patients develops refractory or complicated forms characterized by persistent immune activation and increased risk of malignant transformation. These conditions challenge the traditional view of CeD as a fully reversible, antigen-driven disorder. This narrative review reframes refractory and complicated CeD as a biological continuum driven by sustained immune dysregulation and partial independence from the antigenic trigger. Literature was identified through PubMed and Embase searches (January 2000-March 2026), focusing on clinical, translational, and molecular studies relevant to refractory and complicated CeD. Current definitions and the clinical spectrum are discussed, spanning refractory CeD types 1 and 2 (RCeD1 and RCeD2), ulcerative jejunoileitis, intestinal lymphomas, and small bowel adenocarcinoma. Immunological mechanisms, including aberrant intraepithelial lymphocyte populations, clonal T-cell expansions, and cytokine-driven survival pathways, especially IL-15 signaling, are discussed. Evidence linking chronic inflammation, immune escape, and lymphoproliferation is reviewed. Current diagnostic and therapeutic strategies remain inadequate to identify early immune escape and pre-malignant evolution. A shift toward biologically driven risk stratification and integration of molecular diagnostics is essential to enable early identification and targeted intervention in high-risk patients.